CA2872002C - Pyrazole derivative and use thereof for medical purposes - Google Patents

Pyrazole derivative and use thereof for medical purposes Download PDF

Info

Publication number
CA2872002C
CA2872002C CA2872002A CA2872002A CA2872002C CA 2872002 C CA2872002 C CA 2872002C CA 2872002 A CA2872002 A CA 2872002A CA 2872002 A CA2872002 A CA 2872002A CA 2872002 C CA2872002 C CA 2872002C
Authority
CA
Canada
Prior art keywords
constipation
compound
group
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2872002A
Other languages
English (en)
French (fr)
Other versions
CA2872002A1 (en
Inventor
Masayuki Isaji
Masaaki TAKEMURA
Hidetoshi Isawa
Yukihiko Hotei
Itaru MIYASHITA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CA2872002A1 publication Critical patent/CA2872002A1/en
Application granted granted Critical
Publication of CA2872002C publication Critical patent/CA2872002C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2872002A 2012-05-07 2013-05-02 Pyrazole derivative and use thereof for medical purposes Active CA2872002C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-105847 2012-05-07
JP2012105847 2012-05-07
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
CA2872002A1 CA2872002A1 (en) 2013-11-14
CA2872002C true CA2872002C (en) 2019-01-15

Family

ID=49550709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872002A Active CA2872002C (en) 2012-05-07 2013-05-02 Pyrazole derivative and use thereof for medical purposes

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
PL2848254T3 (pl) * 2012-05-07 2017-03-31 Kissei Pharmaceutical Co., Ltd. Pochodne pirazolu i ich zastosowanie w celach medycznych
MX346453B (es) 2013-02-04 2017-03-17 Taisho Pharmaceutical Co Ltd Medicamento profilactico o terapeutico para el estreñimiento.
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
WO2015199146A1 (ja) * 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその安定化方法
BR112020019624A8 (pt) 2018-03-28 2022-03-03 Avolynt Método para tratar a hipoglicemia pós-prandial
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP3810084A1 (en) 2018-06-20 2021-04-28 Albireo AB Pharmaceutical formulation of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
DK3921028T3 (da) 2019-02-06 2023-01-23 Albireo Ab Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7696897B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN116157389B (zh) 2020-08-03 2026-02-10 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
CA2709530C (en) 2007-12-27 2016-02-23 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
US8354382B2 (en) 2008-04-16 2013-01-15 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PL2848254T3 (pl) * 2012-05-07 2017-03-31 Kissei Pharmaceutical Co., Ltd. Pochodne pirazolu i ich zastosowanie w celach medycznych

Also Published As

Publication number Publication date
BR112014027841B1 (pt) 2022-08-09
RU2602739C2 (ru) 2016-11-20
US9694027B2 (en) 2017-07-04
US20150141631A1 (en) 2015-05-21
EP2848254B1 (en) 2016-08-03
DK2848254T3 (en) 2016-10-31
JPWO2013168671A1 (ja) 2016-01-07
PL2848254T3 (pl) 2017-03-31
PT2848254T (pt) 2016-10-05
CA2872002A1 (en) 2013-11-14
CN104284665B (zh) 2016-11-16
US9273085B2 (en) 2016-03-01
WO2013168671A1 (ja) 2013-11-14
JP2015083580A (ja) 2015-04-30
KR101868991B1 (ko) 2018-06-19
BR112014027841A2 (pt) 2017-06-27
AU2013258566B2 (en) 2017-03-16
KR20150013671A (ko) 2015-02-05
JP5663699B2 (ja) 2015-02-04
CN104284665A (zh) 2015-01-14
AU2013258566A1 (en) 2014-11-27
MX359988B (es) 2018-10-18
JP6105546B2 (ja) 2017-03-29
ES2601127T3 (es) 2017-02-14
HK1204773A1 (en) 2015-12-04
US20160129031A1 (en) 2016-05-12
EP2848254A4 (en) 2015-07-15
RU2014149181A (ru) 2016-06-27
MX2014013696A (es) 2015-02-05
EP2848254A1 (en) 2015-03-18
BR112014027841A8 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
CA2872002C (en) Pyrazole derivative and use thereof for medical purposes
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
CN103338768B (zh) 胃和结肠的配制剂及其制备和使用方法
US20040092511A1 (en) Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20170368025A1 (en) Combination of canagliflozin and probenecid for the treament of hyperuricemia
US11834445B2 (en) Polymorphic forms of metopimazine
KR20150139535A (ko) 설사 치료를 위한 방법 및 생산물
US20200038413A1 (en) Methods of treating parkinson's disease using aminosterol compositions
HK1204773B (en) Pyrazole derivative and use thereof for medical purposes
KR102078433B1 (ko) 변비증의 예방 또는 치료약
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
US20200038419A1 (en) Methods of treating multiple system atrophy using aminosterol compositions
US20200038418A1 (en) Methods of treating autism spectrum disorder using aminosterol compositions
US20110269792A1 (en) Compositions useful for treating irritable bowel syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171207

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402